What is wrong with orphan drug policies?

Value in Health

Volumn 15, Issue 8, 2012, Pages 1185-1191

  Côté, André ^a   Keating, Bernard ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

health policy; hospital and public health systems; orphan drugs; outcomes; stakeholder strategies

Indexed keywords

ORPHAN DRUG;

ARTICLE; DRUG BIOAVAILABILITY; DRUG COST; DRUG MANUFACTURE; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; PRIORITY JOURNAL; REIMBURSEMENT;

COSTS AND COST ANALYSIS; DRUG INDUSTRY; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; OFF-LABEL USE; ORPHAN DRUG PRODUCTION; POLICY; UNITED STATES;

EID: 84871184065     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.09.004     Document Type: Article

References (27)

1. M.E. Haffner, J. Whitley, and M. Moses Two decades of orphan product development Nat Rev Drug Discov 1 2002 821 825 (Pubitemid 37361565)
2. R.Y. Cheung, J.C. Cohen, and P. Illingworth Orphan drug policies: implications for the United States, Canada, and developing countries Health Law J 12 2004 183 200
3. M. Thamer, N. Brennan, and R. Semansky A cross-national comparison of orphan drug policies: implications for the U.S. Orphan Drug Act J Health Polit Policy Law 23 1998 265 290 (Pubitemid 28166785)
4. MSPS. Assurer l'équité pour l'accès au diagnostic, au traitement et à la prise en charge. In: Plan National Maladies Rares 2005-2008. 2004.
5. CORD. Guiding documents. In: Towards a Canadian Orphan Drug Policy (ODP). 2005.
6. A. Rinaldi Adopting an orphan EMBO Rep 6 2005 507 510 (Pubitemid 40973956)
7. Vidoudez M. Médicaments orphelins: un statut particulier? Lausanne, Suisse: Institut d'Economie et Management de la Santé (lEMS), 2005.
8. P. Borensztein [Orphan medicinal products: assessment after 5 years of European legislation] Med Sci (Paris) 22 2006 71 74 (Pubitemid 43128232)
9. N. Bosanquet, G. Domenighetti, and A. Beresniak Equity, access and economic evaluation in rare diseases: the impact of orphan drug legislation on health policy and patient care Pharm Dev Regul 1 2003 151 157
10. T. Maeder The orphan drug backlash Sci Am 288 2003 80 87
11. P. Thornton Opportunities in Orphan Drugs-Strategies for Developing Maximum Returns from Niche Indications 2010 Business Insights Ltd London
12. de Varax AM, Letellier M, Börtlein G, ALCIMED. Study on Orphan Drugs: Phase I-Overview of the Conditions for Marketing Orphan Drugs in Europe. Paris, France: ALCIMED, 2005.
13. F.R. Lichtenberg The benefits to society of new drugs: a survey of the econometric evidence Proc Fed Res Bank Dallas Sep 2003 43 59
14. M.E. Haffner, J. Torrent-Farnell, and P.D. Maher Does orphan drug legislation really answer the needs of patients? Lancet 371 2008 2041 2044 (Pubitemid 351818196)
15. S.J. Gavel The oncology pipeline: maturing, competitive, and growing? Oncol Bus Rev Sep 2008 14 16
16. L. Seachrist Senators seek reform of Orphan Drug Act J Natl Cancer Inst 85 1993 1984 1985 (Pubitemid 24000976)
17. P.G. Casali The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO) Ann Oncol 18 2007 1923 1925 (Pubitemid 350286226)
18. C. McCabe, A. Tsuchiya, K. Claxton, and J. Raftery Assessing the economic challenges posed by orphan drugs: a comment on Drummond et al Int J Technol Assess Health Care 23 2007 397 401 (Pubitemid 46956891)
19. Office of Inspector General The Orphan Drug Act: implementation and impact 2001 Department of Health and Human Services San Francisco, CA
20. J.V. Leonard, and S. Richmond Pricing of orphan drugs Lancet 373 2009 462
21. A. Schieppati, G. Remuzzi, and S. Garattini Modulating the profit motive to meet needs of the less-developed world Lancet 358 2001 1638 1641 (Pubitemid 33101921)
22. N. DePaulsen Abandonment or Access: Canada's Orphan Drug Policy. Université de Toronto 2004 Toronto, Canada
23. Nature Medecine Turning a blind eye Nat Med 14 2008 1
24. M. Ratner, and T. Gura Off-label or off-limits? Nat Biotechnol 26 2008 867 875
25. C. Lenk, P. Koch, H. Zappel, and C. Wiesemann Off-label off-limits? Parental awareness and attitudes towards off-label use in paediatrics Eur J Pediatr 168 2009 1473 1478
26. J. Cohen, and A. Wilson New challenges to Medicare beneficiary access to mAbs MAbs 1 2009 56 66
27. A. Sahoo Drug Approval Trends at the FDA and EMEA: Process Improvements, Heightened Scrutiny and Industry Response 2008 Business Insights Ltd London